The real-world experience with nivolumab in previously treated patients with advanced non-small cell lung cancer from a cancer center in India
{{output}}
Background: PDL-1 inhibitors have emerged as the new standard of care for second line treatment of NSCLC. Methods: Eligible patients included, ... ...
